株式会社日本生物製剤
Japan Bio Products Co., Ltd. is a Tokyo-based specialist in placenta-based products serving medical professionals and beauty consumers through its LAENNEC® pharmaceutical line and LNC Cosmetic Series skincare brands, currently expanding from Japan into the EU market.
- Company typePrivate
- Founded-
- Headquarters—
- Headcount1–10
- GTM typeB2B and B2C
- OfferingHardware or Manufacturing
What 株式会社日本生物製剤 does
Japan Bio Products Co., Ltd. (株式会社日本生物製剤, "JBP") is a Tokyo-based specialist in placenta-based products operating across medical treatment, health, and beauty applications. The company's core asset is its proprietary JBP Placenta Extract, used in its flagship pharmaceutical/health product LAENNEC® (a placental injectable historically associated with Japanese clinics and now shipping into the EU as of March 2026) and in its consumer skincare line, the LNC Cosmetic Series (including LNC DiaSerum). JBP positions itself as the world-leading company in placenta-based products, emphasizing research into placenta composition and mechanism, and maintains product authentication infrastructure to combat counterfeits.
The business operates a hybrid go-to-market model: a direct-to-consumer online shop (jbp-shop-jp.myshopify.com) serves Japanese consumers, while a new channel-partner motion seeks EU distributors for the LNC skincare line following the May 2026 CPNP registration of LNC DiaSerum. Customer segmentation is hybrid, with two primary personas — medical professionals (LAENNEC) and health-and-beauty consumers (LNC) — addressed through distinct channels and product SKUs. The company distributes via its multilingual website (Japanese, English, Simplified and Traditional Chinese), official Facebook and Instagram accounts, and a global online storefront. Pricing is not publicly disclosed.
The company operates with a notably lean team of 7 employees, indicating a small specialist organization rather than a large-scale manufacturer. Financials, headcount trend, funding history, and revenue are not disclosed in the available data. Recent strategic activity in 2026 — EU shipping of LAENNEC, CPNP registration, an EU distributor search, and the discontinuation of JBP Skin Poration — points to a portfolio rationalization and internationalization push centered on the LNC skincare brand and the LAENNEC pharmaceutical product.
株式会社日本生物製剤 firmographics
Firmographics- Name
- 株式会社日本生物製剤
- Legal name
- Japan Bio Products Co., Ltd.
- Website
- https://jbp.placenta.co.jp
- Company type
- Private
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Japan Bio Products Co., Ltd. is a Tokyo-based specialist in placenta-based products serving medical professionals and beauty consumers through its LAENNEC® pharmaceutical line and LNC Cosmetic Series skincare brands, currently expanding from Japan into the EU market.
- Ownership category
- akta.pro rank
株式会社日本生物製剤 business model
Business model- GTM type
- B2B and B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Technology or R&D, Marketing or Sales, Operations
Revenue model
- Placenta-based Products: Sale of placenta-based products including LAENNEC for medical/aesthetic applications and LNC Cosmetic Series for skincare. Products are distributed through direct online sales and channel partners.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels4 records
株式会社日本生物製剤 product offering
Product offeringCore offering
Japan Bio Products Co., Ltd. (JBP) develops, manufactures and sells placenta-based products used in medical treatment, health, and beauty applications. Its commercial lineup centers on proprietary JBP Placenta Extract, encompassing the LAENNEC pharmaceutical/health product, the LNC Cosmetic Series anti-aging skincare brand, and LNC DiaSerum. Products are sold directly to consumers through the company's online shop and through distributor and medical-professional channels.
Product overview
Japan Bio Products Co., Ltd. is a world-leading company specializing in placenta-based products for medical treatment, health, and beauty applications. The company offers a portfolio centered on JBP Placenta Extract as its core ingredient, supported by pharmaceutical/health products like LAENNEC® and skincare brands including the LNC Cosmetic Series (featuring LNC DiaSerum). JBP operates globally with online shop capabilities and is currently expanding into the European market.
Differentiator
Problem solved
Functional benefit
Brands
- LAENNEC®: Placenta-based product brand available for shipping in EU.
- LNC Cosmetic Series
- LNC DiaSerum
Products and services
- JBP Placenta Extract
Companies that use 株式会社日本生物製剤
Customer profileSegments2 records
Ideal customer profiles3 records
株式会社日本生物製剤 technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
株式会社日本生物製剤 partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- EU Sales Partners/DistributorscoreJBP is actively seeking EU sales partners and distributors for their high-quality skincare brand 'LNC Cosmetic Series'. This partnership supports the company's expansion into the European market, with LNC DiaSerum already registered with the European Cosmetics Notification Portal (CPNP). The company is looking for distributors to bring Japanese anti-aging cosmetics to Europe.
Scale indicators1 record
Recent moves5 records
Expansion highlights4 records
株式会社日本生物製剤 competitors and assessment
Company assessmentBroad incumbents
- KOSÉ Corporation: Major Japanese cosmetics company operating premium skincare and anti-aging lines (Decorté, Sekkisei, ONE BY KOSÉ), comparable to JBP in serving the premium Japanese skincare consumer with cosmeceutical positioning.
- DHC Corporation:
- FANCL Corporation: Japanese skincare and health supplements company with a strong direct-to-consumer/mail-order model and additive-free beauty positioning, closely mirroring JBP's combination of cosmetic skincare and wellness supplements sold online.
- Pola Orbis Holdings, Inc. Japanese premium cosmetics group with flagship anti-aging brand POLA and a portfolio of skincare brands; comparable to JBP in targeting the high-end Japanese anti-aging skincare consumer with a direct-marketing-leaning model.
- Galderma SA: Global dermatology and medical aesthetics company (Cetaphil, Restylane, Sculptra) operating at the intersection of prescription skincare, aesthetics, and consumer dermocosmetics, comparable to JBP in targeting medical professionals and aesthetic consumers in the medical-beauty crossover.
- Shiseido Co., Ltd. One of Japan's largest global beauty companies with premium anti-aging skincare brands (SHISEIDO, Cle de Peau, ELIXIR) and is likely to overlap with JBP's LNC Cosmetic Series in target customers (anti-aging, premium skincare consumers) and channels.
Regional players
- Hugel, Inc. South Korean biopharmaceutical and medical aesthetics company (botulinum toxin, dermal fillers, skincare) that, like JBP, bridges injectable biologic products with consumer beauty, with comparable premium positioning in the regional medical-aesthetics market.
- Mizon Co., Ltd. South Korean cosmetics company whose portfolio includes placenta-based skincare lines and which sells cross-border into Japan and other Asian markets, comparable to JBP in placenta-derived skincare positioning though in a different primary geography.
Direct peers
- Melsmon Pharmaceutical Co., Ltd. Japan-based pharmaceutical company marketing placenta-based injectable products (Melsmon Injection) for medical and aesthetic use, directly competing with JBP's LAENNEC in the same Japanese placenta-pharma niche.
Emerging players
- BeCur Japan Co., Ltd. Japanese placenta-based cosmetics and supplement brand marketed via D2C channels, an emerging niche specialist with strong overlap to JBP in the Japanese placenta beauty and health category.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
株式会社日本生物製剤 social profiles
Digital presence株式会社日本生物製剤 financial estimates
Financial estimateRevenue estimate
Valuation estimate
株式会社日本生物製剤 leadership team
Management profileNumber of profiles
株式会社日本生物製剤 funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
株式会社日本生物製剤 M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about 株式会社日本生物製剤
What does 株式会社日本生物製剤 do?
Japan Bio Products Co., Ltd. (JBP) develops, manufactures and sells placenta-based products used in medical treatment, health, and beauty applications. Its commercial lineup centers on proprietary JBP Placenta Extract, encompassing the LAENNEC pharmaceutical/health product, the LNC Cosmetic Series anti-aging skincare brand, and LNC DiaSerum. Products are sold directly to consumers through the company's online shop and through distributor and medical-professional channels.
When was 株式会社日本生物製剤 founded?
株式会社日本生物製剤 was founded in -1. It employs 1 to 10 people.
How does 株式会社日本生物製剤 make money?
One revenue line is on record: placenta-based Products.
Who are 株式会社日本生物製剤's main competitors?
Broad incumbents on record are KOSÉ Corporation, DHC Corporation, FANCL Corporation, Pola Orbis Holdings, Inc., Galderma SA and Shiseido Co., Ltd.. Regional players are Hugel, Inc. and Mizon Co., Ltd.. Melsmon Pharmaceutical Co., Ltd. is listed as a direct peer. BeCur Japan Co., Ltd. is listed as an emerging player.
Does 株式会社日本生物製剤 have an API?
No public API is recorded for 株式会社日本生物製剤.